LIPELLA PHARMACEUTICALS INC.
Close on Oct 19, 2026
- Market cap
- $2.27K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2023 Ended Mar 31, 2023 | Apr 3, 2023 | During market hours | – | – | – |
Press releases
Announcements Lipella Pharmaceuticals filed with the SEC
Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
1 lipellapharmaceuticals.com A Clinical Stage Biotechnology Company Transforming Care with Innovative Mucosal Delivery Solutions Corporate Presentation September 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
the past few days, I have received many calls, texts, and emails asking questions about our status. In a genuine effort to keep
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Lipella Pharmaceuticals Announces 1-for-8 Reverse
Other events · EX-99.1 to Form 8-K
Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1#2 to Form 8-K
A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need NASDAQ:LIPO lipellapharmaceuticals.com
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Reports 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
to Mucosal Surfaces Biotech Showcase 2023TM January 11, 2023 Wednesday, 2:00 PM ET Track: Yosemite A (Ballroom Level) (Nasdaq:
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K